26 research outputs found
Interferon-Alpha Mediates Restriction of Human Immunodeficiency Virus Type-1 Replication in Primary Human Macrophages at an Early Stage of Replication
Type I interferons (IFNα and ÎČ) are induced directly in response to viral infection, resulting in an antiviral state for the cell. In vitro studies have shown that IFNα is a potent inhibitor of viral replication; however, its role in HIV-1 infection is incompletely understood. In this study we describe the ability of IFNα to restrict HIV-1 infection in primary human macrophages in contrast to peripheral blood mononuclear cells and monocyte-derived dendritic cells. Inhibition to HIV-1 replication in cells pretreated with IFNα occurred at an early stage in the virus life cycle. Late viral events such as budding and subsequent rounds of infection were not affected by IFNα treatment. Analysis of early and late HIV-1 reverse transcripts and integrated proviral DNA confirmed an early post entry role for IFNα. First strand cDNA synthesis was slightly reduced but late and integrated products were severely depleted, suggesting that initiation or the nucleic acid intermediates of reverse transcription are targeted. The depletion of integrated provirus is disproportionally greater than that of viral cDNA synthesis suggesting the possibility of a least an additional later target. A role for either cellular protein APOBEC3G or tetherin in this IFNα mediated restriction has been excluded. Vpu, previously shown by others to rescue a viral budding restriction by tetherin, could not overcome this IFNα induced effect. Determining both the viral determinants and cellular proteins involved may lead to novel therapeutic approaches. Our results add to the understanding of HIV-1 restriction by IFNα
The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Our objective was to evaluate the non-germinal center (GC) profile as a marker for response and survival
in DLBCL and to compare the characteristics of patients with GC and non-GC DLBCL treated with
rituximab-containing regimens. In this patient-level meta-analysis, retrospective data from 712 newly
diagnosed DLBCL patients treated with chemoimmunotherapy from 7 centers were analyzed. GC and
non-GC profiles were defined according to the Hans algorithm. Although the non-GC profile showed a
trend towards worse overall survival (HR 1.24, 95% CI 0.92\u20131.66; p = 0.15) and progression-free survival
(HR 1.29, 95% CI 0.96\u20131.73; p = 0.09), it did not retain its value in the multivariate survival analysis. Additionally,
the non-GC profile was independently associated with worse complete response rates (OR 0.55,
95% CI 0.37\u20130.83; p < 0.01) in the multivariate logistic regression analysis. Interestingly, Asian patients
had higher proportion of GC DLBCL (p = 0.01).
\ua